TIGIT Combo Delivers Significant Improvement in Lung Cancer Treatment at ESMO 2024

ESMO 2024: iTeos Therapeutics and GSK presented significant findings from their phase 2 trial of a TIGIT and PD-1 combination therapy. The GALAXIES Lung-201 trial evaluated the combination of belrestotug (anti-TIGIT antibody) and dostarlimab (Jemperli, anti-PD-1) in patients with previously untreated, unresectable, or metastatic PD-L1-high non-small cell lung cancer (NSCLC).
Key Highlights Include:
The combination therapy resulted in a 30% higher tumor shrinkage compared to PD-1 monotherapy.
Overall response rates (ORR) reached 63.3%, 65.6%, and 76.7% in the three different dose groups, compared to 37.5% in the control group.
Confirmed overall response rates (cORR) of ~60% in the combination groups, compared to 28.1% with monotherapy.
Phase 3 GALAXIES Lung-301 trial has been launched with a planned enrollment of 1,000 patients, with completion expected by 2028.
These findings highlight the potential of TIGIT/PD-1 combination therapy to significantly improve treatment outcomes for lung cancer patients. Watch the full video to learn more about this exciting advancement in immunotherapy.